Biogen
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Biogen, UCB get the lupus data they've waited two decades for
Biogen and UCB report positive late-stage trial results for experimental lupus drug dapirolizumab pegol, planning a second Phase 3 trial. The drug showed significant improvement over placebo when combined with standard care, with detailed results to be presented at a medical meeting. This could lead to a new therapy for systemic lupus erythematosus (SLE), a challenging autoimmune disease with limited treatment options.
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
UCB and Biogen report positive Phase 3 PHOENYCS GO study results for dapirolizumab pegol in treating moderate-to-severe systemic lupus erythematosus (SLE), meeting primary endpoint of improved disease activity after 48 weeks. The safety profile aligns with previous studies, and a second Phase 3 trial, PHOENYCS FLY, is planned for 2024.
EMA issues positive view on Samsung Bioepis' Eylea biosimilar
Samsung Bioepis received a positive scientific opinion from the EMA’s CHMP for Opuviz (SB15), a biosimilar referencing Eylea, after reviewing its MAA. A positive CHMP opinion typically leads to EC approval within 2-3 months. Opuviz targets ophthalmic diseases like wet AMD, inhibiting VEGF to prevent new blood vessel formation. Biogen, Samsung Bioepis’ partner, will manage European marketing and distribution post-approval.
Chris Viehbacher Biogen CEO supports PM Modi's views on inclusive technology for better
Biogen CEO Chris Viehbacher praises PM Modi's vision of making India central to 21st-century tech progress, highlighting India's talented, youthful population. Viehbacher emphasizes technology's role in inclusive healthcare and India's potential as a global tech hub, aligning with Modi's focus on societal benefits from tech advancements.
Biogen CEO supports PM Modi's views on inclusive technology for better healthcare
Biogen CEO Chris Viehbacher supports PM Modi's vision of India as a tech leader, emphasizing the importance of inclusive technology for better healthcare, leveraging India's talented and youthful population.
Samsung Bioepis, Biogen receive positive CHMP opinion for aflibercept biosimilar, Opuviz
Samsung Bioepis and Biogen announce EMA's CHMP positive opinion for Opuviz, a biosimilar referencing Eylea, recommended for approval in adult patients for treating neovascular AMD, RVO, DME, and myopic CNV. The CHMP's decision is based on clinical data showing equivalent efficacy and comparable safety profiles between Opuviz and reference aflibercept. The positive opinion will be referred to the EC for a marketing authorization decision.
PM Modi attends 'fruitful' roundtable meeting with tech CEOs in New York
PM Modi held a 'fruitful' roundtable with US tech CEOs in NY, discussing AI, quantum, biotech, computing, and semiconductors. He emphasized India's growth prospects, IP protection, and fostering tech innovation, aiming to make India a global hub for semiconductor manufacturing and a biotech powerhouse.
Investing in This Healthcare Stock Could Be Like Catching Nvidia at the Dawn of the AI Boom
OpenAI's ChatGPT release in 2022 boosted AI euphoria, benefiting Nvidia. Eli Lilly, the 'Nvidia of the GLP-1 and weight loss space,' is poised for growth with its GLP-1 medicines, Mounjaro and Zepbound, and its Alzheimer's candidate, donanemab. Lilly's partnership with OpenAI aims to leverage generative AI for healthcare breakthroughs.
Personalized Precision Medicine Market Share | 2031 Forecast
The global Personalized Precision Medicine Market report offers detailed segmentation and strategic guidance, covering manufacturers, regions, product categories, and applications. Key insights include market evolution, current conditions, future projections, and analysis of key players like Agilent Technologies, Biogen, Johnson & Johnson, and Novartis. The report aids stakeholders in navigating market dynamics and capitalizing on opportunities.
Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ
Samsung Bioepis and Biogen's OPUVIZ™, a biosimilar referencing Eylea (aflibercept), recommended for marketing authorization by the European Medicines Agency for treating neovascular AMD, macular oedema secondary to RVO, DME, and myopic CNV.
© Copyright 2025. All Rights Reserved by MedPath